Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …
Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis.
Uterine fibroids and endometriosis are among the most common conditions encountered in gynaecological practice. Fibroids affect 30-70% of women, with up to half experiencing symptoms that significantly impair quality of …
Prolonged oral GnRH-antagonist administration before euploid embryo transfer in patients with endometriosis: a prospective randomized pilot non-inferiority trial.
Is oral administration of a gonadotrophin releasing hormone (GnRH) antagonist for 2 months before euploid embryo transfer in patients with endometriosis non-inferior to intramuscular administration of a long-acting GnRH agonist …
'Ovariostasis' as the main preventive and therapeutic strategy for gynecological pathologies in women of reproductive age.
Ovariostasis is a reversible and temporary suspension of the cyclic ovarian activity, characterized by anovulation and hypogonadotropinemia (low serum concentrations of FSH and LH), which can be observed in case …